107 289

Cited 2 times in

Significant elevation of aqueous endothelin-1 in central retinal vein occlusion

 Hae Min Kang  ;  Md Hasanuzzaman  ;  So Won Kim  ;  Hyoung Jun Koh  ;  Sung Chul Lee 
 PLOS ONE, Vol.16(6) : e0252530, 2021-06 
Journal Title
Issue Date
Aged ; Bevacizumab / therapeutic use ; Endothelin-1 / metabolism* ; Female ; Humans ; Macular Edema / metabolism ; Male ; Middle Aged ; Prospective Studies ; Retinal Vein Occlusion / drug therapy ; Retinal Vein Occlusion / metabolism* ; Visual Acuity / drug effects
Purpose: To investigate aqueous humor concentrations of endothelin-1 (ET-1) in patients with central retinal vein occlusion (CRVO) compared with patients with branch retinal vein occlusion (BRVO) and a normal control group.

Methods: A total 80 subjects were included in this prospective study, including 15 patients with CRVO, 20 patients with BRVO, and 45 patients who underwent cataract surgery and had no concomitant ocular disease. Aqueous humor levels of ET-1 were obtained before intravitreal bevacizumab injection (IVB) and after 1 month.

Results: At baseline, the mean aqueous ET-1 level was 12.7±3.6 pg/mL in the CRVO group, 8.0±2.3 pg/mL in the BRVO group, and 2.0±0.9 pg/mL in the control group (P<0.001). After IVB, the mean aqueous level of ET-1 was 3.4±1.9 pg/mL (0.5-6.9 pg/mL) in the CRVO group and 1.8±1.0 pg/mL (0.3-3.2 pg/mL) in the BRVO group (P = 0.008). The mean aqueous ET-1 level was significantly reduced in both the patients with CRVO and those with BRVO (P<0.001).

Conclusion: The mean aqueous humor ET-1 level was significant higher in the patients with CRVO than those with BRVO and in the control group. After IVB, the mean level was significantly reduced in both the patients with CRVO and those with BRVO.
Files in This Item:
T202126076.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Koh, Hyoung Jun(고형준) ORCID logo https://orcid.org/0000-0002-5932-8516
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.